HRP20230693T1 - Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti - Google Patents
Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti Download PDFInfo
- Publication number
- HRP20230693T1 HRP20230693T1 HRP20230693TT HRP20230693T HRP20230693T1 HR P20230693 T1 HRP20230693 T1 HR P20230693T1 HR P20230693T T HRP20230693T T HR P20230693TT HR P20230693 T HRP20230693 T HR P20230693T HR P20230693 T1 HRP20230693 T1 HR P20230693T1
- Authority
- HR
- Croatia
- Prior art keywords
- donepezil
- acetylcholinesterase inhibitor
- idalopirdine
- tetrafluoropropoxy
- rivastigmine
- Prior art date
Links
- YBAWYTYNMZWMMJ-UHFFFAOYSA-N 2-(6-fluoro-1h-indol-3-yl)-n-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine Chemical compound FC(F)C(F)(F)COC1=CC=CC(CNCCC=2C3=CC=C(F)C=C3NC=2)=C1 YBAWYTYNMZWMMJ-UHFFFAOYSA-N 0.000 title claims 13
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title claims 8
- 239000000544 cholinesterase inhibitor Substances 0.000 title claims 8
- 229950005109 idalopirdine Drugs 0.000 title claims 5
- 208000018737 Parkinson disease Diseases 0.000 title claims 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 20
- 229960003530 donepezil Drugs 0.000 claims 10
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 8
- 229960004136 rivastigmine Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin (idalopirdin) ili njegova farmaceutski prihvatljiva sol i inhibitor acetilkolinesteraze odabran od skupine koja se sastoji od donepezila i rivastigmina za uporabu u liječenju Parkinsonove bolesti, naznačen time što se liječenje Parkinsonove bolesti sastoji od smanjenja padova kod pacijenata oboljelih od parkinsonove bolesti.
2. N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin (idalopirdin) ili njegova farmaceutski prihvatljiva sol i inhibitor acetilkolinesteraze odabran od skupine koja se sastoji od donepezila i rivastigmina za uporabu u liječenju prema zahtjevu 1, naznačen time što je dnevna doza idalopirdina od 10 mg do 100 mg.
3. N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin (idalopirdin) ili njegova farmaceutski prihvatljiva sol i inhibitor acetilkolinesteraze odabran od skupine koja se sastoji od donepezila i rivastigmina za uporabu u liječenju prema zahtjevu 1, naznačen time što je dnevna doza idalopirdina od 30 mg do 60 mg.
4. N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin (idalopirdin) ili njegova farmaceutski prihvatljiva sol i inhibitor acetilkolinesteraze odabran od skupine koja se sastoji od donepezila i rivastigmina za uporabu u liječenju prema bilo kojem od zahtjeva 1-3, naznačen time što je inhibitor acetilkolinesteraze donepezil.
5. N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin (idalopirdin) ili njegova farmaceutski prihvatljiva sol i inhibitor acetilkolinesteraze odabran od skupine koja se sastoji od donepezila i rivastigmina za uporabu u liječenju prema bilo kojem od zahtjeva 1-3, naznačen time što je inhibitor acetilkolinesteraze rivastigmin.
6. N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin (idalopirdin) ili njegova farmaceutski prihvatljiva sol i donepezil za uporabu u liječenju prema zahtjevu 4, naznačen time što je doza donepezila od 1 do 30 mg.
7. N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin (idalopirdin) ili njegova farmaceutski prihvatljiva sol i donepezil za uporabu u liječenju prema zahtjevu 4, naznačen time što je doza donepezila od 5 do 23 mg.
8. N-(2-(6-fluoro-1H-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin (idalopirdin) ili njegova farmaceutski prihvatljiva sol i rivastigmin za uporabu u liječenju prema zahtjevu 5, naznačen time što je doza rivastigmina od 1 do 20 mg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600248 | 2016-04-26 | ||
| PCT/EP2017/059739 WO2017186686A1 (en) | 2016-04-26 | 2017-04-25 | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |
| EP17719255.6A EP3448430B1 (en) | 2016-04-26 | 2017-04-25 | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20230693T1 true HRP20230693T1 (hr) | 2023-10-13 |
| HRP20230693T8 HRP20230693T8 (hr) | 2023-11-10 |
Family
ID=58632402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230693TT HRP20230693T8 (hr) | 2016-04-26 | 2017-04-25 | Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10383849B2 (hr) |
| EP (1) | EP3448430B1 (hr) |
| JP (1) | JP6992004B2 (hr) |
| KR (1) | KR102473545B1 (hr) |
| CN (1) | CN109069650A (hr) |
| AU (1) | AU2017256623B2 (hr) |
| BR (1) | BR112017026928B1 (hr) |
| CA (1) | CA3020557C (hr) |
| CL (1) | CL2018003013A1 (hr) |
| CY (1) | CY1126138T1 (hr) |
| DK (1) | DK3448430T3 (hr) |
| ES (1) | ES2949288T3 (hr) |
| FI (1) | FI3448430T3 (hr) |
| HR (1) | HRP20230693T8 (hr) |
| HU (1) | HUE062626T2 (hr) |
| IL (1) | IL262546B (hr) |
| LT (1) | LT3448430T (hr) |
| MX (1) | MX2018013031A (hr) |
| PL (1) | PL3448430T3 (hr) |
| PT (1) | PT3448430T (hr) |
| RS (1) | RS64307B1 (hr) |
| RU (1) | RU2742173C2 (hr) |
| SG (1) | SG11201809297UA (hr) |
| SI (1) | SI3448430T1 (hr) |
| TW (1) | TW201806621A (hr) |
| WO (1) | WO2017186686A1 (hr) |
| ZA (1) | ZA201806864B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7167065B2 (ja) | 2017-05-24 | 2022-11-08 | ハー・ルンドベック・アクチエゼルスカベット | Ａｐｏｅ４アレルを有する患者亜集団におけるアルツハイマー病の治療での使用のための５－ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組み合わせ |
| WO2019240740A1 (en) * | 2017-12-22 | 2019-12-19 | Arasteh Ari Azhir | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| EP1379239B1 (en) * | 2001-03-29 | 2007-09-12 | Eli Lilly And Company | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor |
| ME01224B (me) * | 2005-04-04 | 2013-06-20 | Eisai R&D Man Co Ltd | Jedinjenja dihidropiridina za liječenje neurodegenerativnih bolesti i demencije |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| CA2658959A1 (en) * | 2006-06-23 | 2007-12-27 | Laboratorios Del Dr. Esteve, S.A. | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
| EP2508177A1 (en) * | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| RU2393158C1 (ru) * | 2008-10-06 | 2010-06-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| JO3459B1 (ar) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
-
2017
- 2017-04-25 TW TW106113760A patent/TW201806621A/zh unknown
- 2017-04-25 WO PCT/EP2017/059739 patent/WO2017186686A1/en active Application Filing
- 2017-04-25 AU AU2017256623A patent/AU2017256623B2/en active Active
- 2017-04-25 HR HRP20230693TT patent/HRP20230693T8/hr unknown
- 2017-04-25 JP JP2018555748A patent/JP6992004B2/ja active Active
- 2017-04-25 PL PL17719255.6T patent/PL3448430T3/pl unknown
- 2017-04-25 FI FIEP17719255.6T patent/FI3448430T3/fi active
- 2017-04-25 EP EP17719255.6A patent/EP3448430B1/en active Active
- 2017-04-25 CN CN201780025728.1A patent/CN109069650A/zh active Pending
- 2017-04-25 KR KR1020187030934A patent/KR102473545B1/ko active IP Right Grant
- 2017-04-25 BR BR112017026928-7A patent/BR112017026928B1/pt active IP Right Grant
- 2017-04-25 PT PT177192556T patent/PT3448430T/pt unknown
- 2017-04-25 RU RU2018135846A patent/RU2742173C2/ru active
- 2017-04-25 HU HUE17719255A patent/HUE062626T2/hu unknown
- 2017-04-25 US US15/496,159 patent/US10383849B2/en active Active
- 2017-04-25 CA CA3020557A patent/CA3020557C/en active Active
- 2017-04-25 SI SI201731371T patent/SI3448430T1/sl unknown
- 2017-04-25 RS RS20230489A patent/RS64307B1/sr unknown
- 2017-04-25 ES ES17719255T patent/ES2949288T3/es active Active
- 2017-04-25 SG SG11201809297UA patent/SG11201809297UA/en unknown
- 2017-04-25 LT LTEPPCT/EP2017/059739T patent/LT3448430T/lt unknown
- 2017-04-25 MX MX2018013031A patent/MX2018013031A/es unknown
- 2017-04-25 DK DK17719255.6T patent/DK3448430T3/da active
-
2018
- 2018-10-15 ZA ZA2018/06864A patent/ZA201806864B/en unknown
- 2018-10-24 CL CL2018003013A patent/CL2018003013A1/es unknown
- 2018-10-24 IL IL262546A patent/IL262546B/en unknown
-
2023
- 2023-08-04 CY CY20231100395T patent/CY1126138T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| SG10201903579SA (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| JP2016163571A5 (hr) | ||
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990425A1 (ru) | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| WO2016109217A3 (en) | Btk inhibitors | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| CR20190520A (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
| MA43876A (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| MX2021002322A (es) | Nuevos metodos. | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| HRP20230693T1 (hr) | Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti | |
| JP2015516452A5 (hr) | ||
| MY195054A (en) | Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and use Thereof | |
| ZA201905309B (en) | Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals | |
| MX2019015280A (es) | Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias. | |
| MY196333A (en) | Intranasal Composition Comprising Betahistine | |
| MX2020012464A (es) | Formulaciones de dantroleno y metodos de uso de dichas formulaciones. | |
| JP2015516451A5 (hr) |